AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00698490 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted herpes simplex (gD) candidate vaccine GSK 208141
Description: Intramuscular injection, 3 doses, 2 different formulations
Study NCT00698490 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes simplex virus containing gD-Alum
Description: Intramuscular injection, 3 doses
Study NCT03871179 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ASD Diagnostic Device
Description: The ASD Diagnostic Device is a machine learning algorithm-based software as a medical device that is incorporated into a parent/caregiver-facing mobile application, the Cognoa App, used outside of a clinical setting
Study NCT03496155 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Build and Support Your Teen's Strengths
Description: This is a clinic based psychoeducational intervention for adolescent patients and their parents to improve parent-teen communication about teen strengths. The intervention is designed, if possible, to coincide with the adolescent patients' well-child visits and consists of the following components: (1) In-person or over the phone orientation session with a trained health coach and parent, (2) Distribution of psychoeducational materials to the parent, (3) Endorsement and delivery of key messages from the health care provider, and (4) Booster phone call placed by the health coach.
Study NCT02081573 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief CBT
Description: During the course of the twice/month diabetes management phone sessions the nurse care manager will work collaboratively with the patient to identify a dysfunctional belief that may be affecting adherence and could be improved by a brief CBT intervention (5-7 minutes). The care manager will utilize the CBT phone app to identify a CBT intervention that will be most appropriate for the situation. Each intervention is described step by step in the app. The nurse will go through the intervention and when completed will assure the patient's understanding.CBT interventions are geared towards helping the patient identify and restructure thinking that is impairing successful self-management of a chronic disease
Study NCT03810625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-0502
Description: D-0502 oral tablets
Study NCT04334265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anluohuaxian
Description: 6g each time, twice a day
Study NCT01506895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darapladib
Description: Experimental compound 160 mg dose
Study NCT01506895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo to match
Study NCT03469323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Succinylcholine
Description: Giving mini-dose succinylcholine to facilitate lung collapse during nonintubated VATS.
Study NCT03469323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Giving placebo (normal saline) to facilitate lung collapse during nonintubated VATS.
Study NCT00571454 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone depression care management
Description: 1 call per week for first 4 weeks~1 call every other week for next 8 weeks
Study NCT00462215 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen
Description: Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Vietnam/1203/2004
Study NCT00462215 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen
Description: Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Vietnam/1203/2004
Study NCT00462215 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen
Description: Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Indonesia/05/2005
Study NCT00462215 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen
Description: Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Indonesia/05/2005
Study NCT00462215 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen
Description: Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 12-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
Study NCT00462215 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen
Description: Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 24-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
Study NCT02767115 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2% GSE mucoadhesive gel
Description: 2% GSE mucoadhesive gel administered in periodontal pockets of GSE group at T0 and 3, 6, and 9 days after T0
Study NCT02767115 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: GSE free mucoadhesive gel
Description: GSE free mucoadhesive gel administered in periodontal pockets of Control group at T0 and 3, 6, and 9 days after T0
Study NCT02639260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl D-mannosamine
Description: dose escalation
Study NCT02587442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RadProtect®
Description: This study will evaluate RadProtect® at sequential, escalating dose levels. Once administration is given, study subjects will be followed during 24 hours of hospitalization according to the final injection timing. All subjects will need to return to the hospital for monitoring at 7+2 days after dosing, and follow-up visits by telephone at Day 3, Day 14+2, and Day 28+2 days will need to be conducted.
Study NCT00500877 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mood Management Phone Counseling for Smoking Cessation
Description: Phone counseling addressed mood management and smoking cessation
Study NCT00500877 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mood Management Phone Counseling for Smoking Cessation
Description: Phone counseling addressed mood management and smoking cessation
Study NCT03587246 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 3DTVUS : Uterine peristaltic frequencies
Description: Perform three-dimensional transvaginal ultrasonography To observe uterine peristaltic frequencies in embryo transfer cycles
Study NCT01443819 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lumbar Transforaminal Epidural Corticosteroid Injection
Description: Injection: Anesthetic/corticosteroid (per randomization); repeat 1-3 times if clinically indicated.~The following drugs will be used for this procedure: 80mg Depo-Medrol and 1% lidocaine. These drugs used for the epidural injections are local anesthetic numbing medicines and cortisone/steroid anti-inflammatory medicines.
Study NCT01443819 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical Therapy
Description: Physical therapy carried out per protocol; 2-3 times per week for a total of 12 treatment sessions (excluding initial evaluation, including exit evaluation, minimum attendance 8/12) to be completed by 6 weeks from initiation of care (within study).~Please note: There will be another PT evaluation at the end of 6 weeks.
Study NCT01443819 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: If subject declines then inquire about enrolment in the observational cohort. Participants in this group (Cohort) will chose their treatment (per-protocol physical therapy, injections, or both) after consulting with their physicians.
Study NCT01474096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: implementation strategy of Breastfeeding
Description: implementation strategy (including training session, information distribution, an opinion leader) of Breastfeeding
Study NCT00345982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serdolect
Description: 16 mg, 12 weeks
Study NCT00345982 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01171326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Minocycline Foam FXFM244
Description: FXFM244 - 1%, FXFM244 - 4% to be applied twice daily during 7 days
Study NCT00232830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug-eluting stent
Description: Cypher Sirolimus-eluting Coronary Stent
Study NCT00232830 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bare-metal stent
Description: any bare-metal stent brand
Study NCT01463722 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Amniotic fluid Lamellar Body Counting
Description: fluid samples were obtained by amniocentesis during normal delivery or before rupturing the membrane in cesarean. The samples were sent to the lab as soon as possible and after centrifuging with 500 round per minute for 3 minutes, they were placed in the cell counter machine (STKR coulter).
Study NCT02664129 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video self-observation
Description: Patients will watch the video of them in acute decompensation phase then they will be asked about their emotions, their understanding and awareness of mental illness
Study NCT02664129 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non Self video observation
Description: Patients will not watch the video of them in acute decompensation phase.
Study NCT05253248 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OMIS
Description: This is an open-label micronutrient supplementation trial in healthy adult volunteers. We are planning to supplement healthy adult volunteers, once a day, with a standard over-the-counter multivitamin supplement for a period of 30 consecutive days.
Study NCT02693275 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Quotient® System iPad Test
Description: See arm/group description
Study NCT01523054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol- Toprol XL
Description: Extended release tablet, 200mg once daily for 4 days
Study NCT01523054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol- Lopressor
Description: Immediate release tablet, Day 1 50 mg four times daily, Day 2, 3 and 4 100 mg twice daily
Study NCT00224874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept \[25 mg subcutaneously twice weekly for up to 4 weeks; discontinue if in complete response by 4 weeks\].
Study NCT00224874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate mofetil (MMF) \[20 mg/kg (maximum 1 gm) orally or intravenously twice daily; continue through prednisone taper, then taper MMF over 4 weeks\].
Study NCT00224874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denileukin Diftitox
Description: Denileukin Diftitox (ONTAK®) \[9 mcg/kg intravenously Days 1, 3, 5, 15, 17, 19\].
Study NCT00224874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: Pentostatin \[1.5 mg/m2 daily for 3 days; Days 1-3 and repeat Days 15-17
Study NCT00845663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: Auto-injection device (test) containing 1 mL of certolizumab pegol liquid formulation, 200 mg/mL; 2 injections
Study NCT00845663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Certolizumab pegol
Description: Pre-filled syringe (reference) containing 1 mL of certolizumab pegol liquid formulation, 200 mg/mL; 2 injections
Study NCT03674008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Description: HSK3486 intravenous (iv) 0.4 mg/kg for induction, and 0.2 mg/kg top-ups for maintenance.
Study NCT03674008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol iv 1.5 mg/kg for induction, and 0.75 mg/kg top-ups for maintenance.
Study NCT01494688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel, at a dose of 80 mg/m\^2 will be administered QW for up to 12 weeks.
Study NCT01494688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5509554
Description: RO5509554 will be administered Q2W, Q3W or initial biweekly followed by monthly maintenance as intravenous (IV) infusion until disease progression, unacceptable toxicity, death or participant refusal, whichever occurs first.
Study NCT03724110 — intervention group
Intervention type: OTHER
Intervention: Telestroke
Description: Telestroke is an audiovisual communication network that allows for coordination of stroke care from a distant 'hub' site (the telestroke provider location) to an originating 'spoke' site (patient location) in a HIPAA compliant fashion. In TELECAST-TIA, inpatient telestroke rounding will be used to oversee the urgent diagnostic TIA evaluation, secondary stroke prevention, and stroke education in patients admitted with TIA.
Study NCT02442479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resistance training
Study NCT02442479 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: resistance training
Study NCT03414866 — intervention group
Intervention type: BEHAVIORAL
Intervention: EQ-5D-5L QOL questionnaire
Description: Written questionnaire
Study NCT01748890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonoelastography
Description: Sonoelastography is an imaging technology predicated on reproducible differences in the backscattered ultrasound signal produced by compression of tissues of varying stiffness.
Study NCT01680679 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Trivalent Influenza Vaccine (TIV)
Study NCT04377425 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 swap test PCR
Description: COVID-19 swap test PCR performed according to hospital standard operating procedures
Study NCT03627026 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples will be collected at different time points:
Description: * Baseline~* Week 6 Day 1~* Week 12 Day 1~If feasible, an optional tumor biopsy specimen will be collected during baseline visit for a maximum of 30 patients included in IUCT-O center.
Study NCT01680679 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Inactivated poliovirus vaccine (IPV), trivalent
Study NCT00783757 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Imaging
Description: TOBI scan performed before the participant starts cancer treatment and at the start of each treatment cycle
Study NCT00820833 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard infant formula
Description: standard infant formula given from 3 to 12 months of age, as per standard requirement
Study NCT01368276 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection
Study NCT01368276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)
Description: 125 µg/m² subcutaneous injection
Study NCT03849365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOOKAD VTP
Description: TOOKAD® VTP consists of the combination of a single, 10-minute IV infusion of TOOKAD® at the dose of 3.66 mg/kg, followed by the illumination of the zone to be treated with a 753-nm laser light delivered through transperineal interstitial optical fibers at a power of 150 mW/cm and light energy of 200 J/cm applied over 22 minutes and 15 seconds.
Study NCT05869097 — intervention group
Intervention type: DRUG
Intervention: Trifluridine/Tipiracil
Description: TAS-102 35 mg/m²orally twice a day on days 1-5 and 8-12, every 28 days
Study NCT00820833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test formula
Description: Test formula with different protein and calorie content than standard formula, given from 3 to 12 months of age. As per standard requirement.
Study NCT00956345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nonacog beta pegol
Description: Cohort to receive a single dose of 25U/kg nonacog beta pegol administered intravenously (into the vein)
Study NCT00956345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nonacog beta pegol
Description: Cohort to receive a single dose of 50U/kg nonacog beta pegol administered intravenously (into the vein)
Study NCT00956345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nonacog beta pegol
Description: Cohort to receive a single dose of 100U/kg nonacog beta pegol administered intravenously (into the vein)
Study NCT00645164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ointment Vehicle
Description: Subject acts as own control. 20 mg under Finn chambers
Study NCT00645164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenaderm
Description: 20 mg under Finn chambers
Study NCT01961336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: 10 mg of testosterone gel applied on the external side of the thigh for 21 days starting from the first day of menstruation prior to initiation of ovarian stimulation with rFSH for IVF/ICSI
Study NCT03067038 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single incision laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy with single port device
Study NCT03067038 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Three port laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy with three port
Study NCT03960905 — intervention group
Intervention type: OTHER
Intervention: Children with the usage of anti-infective drugs
Description: According to the models of population pharmacokinetics,the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children.
Study NCT01372657 — intervention group
Intervention type: OTHER
Intervention: biometry calculation
Study NCT03227679 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Metabolite Ratio
Description: This intervention used information from a genetically-informed biomarker (Nicotine Metabolite Ratio, NMR) to assign one of 3 FDA-approved smoking cessation pharmacotherapies (varenicline, bupropion, or NRT) to participants.
Study NCT03227679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: FDA-approved smoking cessation pharmacotherapy
Study NCT05869097 — intervention group
Intervention type: DRUG
Intervention: Bevacizumab
Description: Bevacizumab 5 mg /kg, intravenously on days 1,15,every 28 days
Study NCT01006668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of sevoflurane
Description: Administration of sevoflurane (SEVORANE) by inhalation until a maximal concentration of 4% of inspired gas.
Study NCT03227679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: FDA-approved smoking cessation pharmacotherapy
Study NCT03227679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: FDA-approved smoking cessation pharmacotherapy
Study NCT02341001 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily text message of support
Study NCT03258567 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab, 480 mg IV every 4 weeks for up to 2 years in subjects with responding disease with clinical benefit if they are tolerating treatment
Study NCT00232739 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CYPHER Sirolimus-eluting Coronary Stent
Description: 2.25 Cypher Sirolimus-eluting Coronary Stent
Study NCT02735681 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: meibomian gland probing
Description: Investigator will do baseline (OSDI) questionnaires prior to probing as well as at 1 week (at home), 1 month, 3months, and 6 months at office visits.
Study NCT02735681 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Left eye Meibomian Gland Probing Control Group
Description: There will be no probing in the left eye. This will be used as a control for the right eye.
Study NCT04468308 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Patients complete the National Eye Institute Visual Function Questionnaire 25 pre-operative, 1 month and 3 month postoperatively.
Study NCT01186029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aprepitant
Description: Emend 40mg by mouth 30 minutes before procedure x 1